Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18F–Fluorodeoxyglucose (18F–FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP study

被引：0
作者：
Christian Kelly-Morland
Sarah Rudman
Paul Nathan
Susan Mallett
Giovanni Montana
Gary Cook
Vicky Goh
机构：
[1] Department of Cancer Imaging,Department of Medical Oncology
[2] King’s College London Division of Imaging Sciences & Biomedical Engineering,Department of Medical Oncology
[3] St Thomas’ Hospital,Birmingham Clinical Trials Unit, Institute of Applied Health Research
[4] Guy’s Hospital,Department of Biomedical Engineering
[5] Mount Vernon Cancer Centre,undefined
[6] University of Birmingham,undefined
[7] King’s College London Division of Imaging Sciences & Biomedical Engineering,undefined
[8] St Thomas’ Hospital,undefined
来源：
BMC Cancer | / 17卷
关键词：
Metastatic renal cell carcinoma; Magnetic resonance imaging; Positron emission tomography; Pet/MRI; Response assessment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 217 条
[1]  
Motzer RJ(2011)New perspectives on the treatment of metastatic renal cell carcinoma: an introduction and historical overview Oncologist 16 1-3
[2]  
Escudier B(2007)Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 125-134
[3]  
Eisen T(2013)Pazopanib versus sunitinib in metastatic renal-cell carcinoma N Engl J Med 369 722-731
[4]  
Stadler WM(2016)Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2103-2111
[5]  
Szczylik C(2008)Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 449-456
[6]  
Oudard S(2010)Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 1061-1068
[7]  
Siebels M(2014)Targeted therapy in metastatic renal carcinoma Cancer Lett 343 156-160
[8]  
Motzer RJ(2015)Nivolumab versus Everolimus in advanced renal-cell carcinoma N Engl J Med 373 1803-1813
[9]  
Hutson TE(2013)Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy Br J Cancer 109 1230-1242
[10]  
Cella D(2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 228-247
12345678910